NCT05058183 - Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

June 5, 2023

Primary Completion Date

December 5, 2025

Study Completion Date

December 5, 2028

Conditions

Breast Cancer

Interventions

DIAGNOSTIC_TEST

ctDNA

Patients with stage 1 HER2 positive and triple negative breast cancer will receive ctDNA test after surgery. Treating clinicians will receive results and may change treatment plans in event of negative test.

Trial Locations (2)

SW3 6JJ

RECRUITING

The Royal Marsden NHS Foundation Trust, Chelsea, London

SM5 5PT

RECRUITING

The Royal Marsden NHS Foundation Trust, Sutton, Sutton